2022-502453-33-00已完成2 期
A Phase 2 Exploratory, Multicenter, Open-Label Trial to Determine the Safety and Preliminary Clinical Activity of GEN1046 in Combination With Anticancer Agents in Subjects With Advanced Endometrial Cancer
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Genmab A/S
- 入组人数
- 43
- 试验地点
- 24
- 主要终点
- Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the investigator
研究概览
简要总结
Evaluate the antitumor activity of GEN1046 in combination with anticancer therapy in subjects with advanced endometrial cancer
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Part 1
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Have a histologically confirmed diagnosis of advanced (unresectable, recurrent, and/or metastatic) endometrial carcinoma that is incurable and for which prior standard first-line treatment has failed.
- •Prior to C1D1, documentation of tumor dMMR/MSI-H status must be available based on previously performed mismatch repair (MMR)/microsatellite instability (MSI) testing results using immunohistochemistry (IHC), polymerase chain reaction (PCR), or next-generation sequencing (NGS) performed with a Food and Drug Administration (FDA)-approved/Conformitè Europëenne (CE)-marked test.
- •Must have progressed on or after at least 1 (but no more than 2) prior line(s) of a systemic chemotherapy regimen for unresectable and/or metastatic endometrial cancer of which at least 1 regimen of platinum-based treatment unless subject is ineligible for or intolerant to platinum.
- •Cohort A only: Must be treatment naive for CPIs including PD-1 or PD-L1 inhibitors and other immune CPIs (eg, anticytotoxic T-lymphocyte-associated protein 4 [CTLA-4], anti-lymphocyte-activation gene 3 [LAG3], anti-T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains [TIGIT]).
- •Cohort B only: Must have received and progressed on or after prior treatment with a PD-1/PD-L1 inhibitor alone or in combination. Moreover, the subject must fulfill the following:Duration of CPI containing treatment and best overall response (BOR) is known, and subject has received a minimum of 2 cycles of CPI.
排除标准
- •Has carcinosarcoma, malignant mixed Műllerian tumor, endometrial leiomyosarcoma, or endometrial stromal sarcomas.
- •Has been exposed to any of the following prior therapies/treatments within the specified timeframes: • Any prior treatment with any type of antitumor vaccine or autologous cell immunotherapy. • Radiotherapy within 14 days before the planned first dose of trial treatment with exception of palliative radiotherapy to bone lesions, which is allowed if completed 7 days prior to trial treatment start. Participants must have recovered from all radiation-related toxicities and/or complications prior to enrollment and must have tapered corticosteroid treatment to ≤10 mg/day at the time of first dose. • Treatment with an anticancer agent, including investigational vaccines within 28 days before or 5 times t1/2, whichever is shorter, prior to the planned first dose of trial treatment or is currently enrolled in an interventional trial. Note: Subjects who are in the follow-up phase of an interventional trial may participate if the subject has not received the investigational agent within 28 days of the first dose of trial treatment. • Prior treatment with live, attenuated vaccines within 30 days prior to initiation of trial treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. Experimental and/or nonauthorized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations are not allowed. • Received granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support within 4 weeks before the planned first dose of trial treatment.
- •Current pneumonitis (any grade) including any radiological change of ongoing pneumonitis at baseline or history of noninfectious drug-, immune-, or radiation-related pneumonitis that has required steroids.
- •Cohort A only: Prior exposure to immune CPIs (eg, anti-PD-1/anti-PD-L1, anti-CTLA-4, anti-LAG3, anti-TIGIT) or agents directed at costimulatory T-cell receptors (eg, 4-1BB, OX40)
- •Cohort B only: • Known history of Grade 3 or higher irAEs that led to treatment discontinuation of a prior immunotherapy treatment • Exposure to any of the following prior therapies/treatments within the specified timeframes: • Prior exposure to immune CPIs other than anti-PD-1/anti-PD-L1 (eg, anti-CTLA-4, anti-LAG3, anti-TIGIT) or agents directed at costimulatory T-cell receptors (eg, 4-1BB, OX40) • PD-1/PD-L1 antibody within 28 days before the planned first dose of trial treatment
结局指标
主要结局
Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the investigator
Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the investigator
次要结局
- Per RECIST 1.1 as assessed by the investigator: • Duration of response (DOR) • Time to response (TTR) • Disease control rate (DCR)
- • Incidence and severity of adverse events (AEs) • Incidence and severity of laboratory abnormalities
研究者
Genmab Trial Information
Scientific
Genmab A/S
研究点 (24)
Loading locations...
相似试验
已完成
4 期
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis2023-504869-23-00AbbVie Deutschland GmbH & Co. KG272
进行中（未招募）
1 期
晚期 / 转移性实体瘤受试者中的安全性、耐受性及药代动力学特征研究CTR20254797254
招募中
1 期
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D MutationNCT07259590Genfleet Therapeutics (Shanghai) Inc.126
招募中
1 期
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsColorectal CancerNon-Small Cell Lung CancerNCT07261631Novartis Pharmaceuticals180
进行中（未招募）
1/2 期
GV20-0251 注射液在晚期实体瘤患者中开展的 I/II 期临床试验CTR20252531350